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Abstract. EGFR, p27kip1 and Skp2, have been implicated in
human cancer development. We have studied these molecules
in a search for molecular markers that may have prognostic
value in head and neck squamous cell carcinomas (HNSCC).
Tissue samples of 62 patients were collected and immuno-
histochemical analysis was carried out for p27kip1, Skp2 and
EGFR protein evaluation. Western blot analysis of p27kip1 was
performed. The p27kip1 expression is frequently down-regulated
in HNSCC (44.4%, 20/45 cases). The immunohistochemical
analysis showed p27kip1 cytoplasmic retention in 7/38
tumors. Strong Skp2 signals were detected at the invasive
edge of the tumor in cells lacking p27kip1 staining. We found
a high EGFR staining in 49% (23/47) of the cases. The
staining tended to be more frequent in lymph node-positive
cases. The dysplastic tissue exhibited no Skp2 immuno-
reactivity, whereas 51.06% (24/47) of invasive tumors
expressed high levels. Of note is that Skp2 overexpression
was the only factor that significantly correlated with a shorter
overall survival in multivariate analysis (p=0.048). Our results
suggest that Skp2 is a useful prognostic marker for HNSCC
management.
Introduction
Head and neck squamous cell carcinoma (HNSCC) remains a
significant cause of morbidity and mortality, afflicting
~500,000 new cases worldwide each year (1). The clinical
course of these tumors cannot be completely predicted by
clinicopathological features. Therefore, new molecular markers
that can be used for a more accurate clinical management of
these tumors are needed (2).
Cell cycle progression is governed by cyclin-dependent
kinases (cdks) that are regulated by phosphorylation, cyclin
binding and cdk inhibitors. The coordinated expression of
cyclins, cdks and cdk inhibitors is often deregulated in cancer.
The cdk inhibitor p27kip1 regulates cellular progression from G1
to S phase (3). The inactivation of p27kip1 has been implicated
in the development of a broad range of human malignancies
suggesting that it plays an important role in human cancer
pathogenesis (4-11).
The regulation of p27kip1 expression occurs predominately
at the post-translational level by a ubiquitin-proteasome-
dependent degradation mechanism. Skp2 is a rate-limiting
component of this machinery (12) and it plays a critical role
in the regulation of p27kip1, a key mediator of PTEN-induced
G1 arrest, through the PI 3-K/Akt/PTEN pathway (13). Skp2
overexpression has been observed in various types of human
tumors (14). The p27kip1 and Skp2 levels are inversely corre-
lated in colorectal cancer (15). These findings suggest that
the enhanced p27kip1 degradation observed in many aggressive
human tumors is attributable to increased levels of Skp2.
However, not all aggressive cancers exhibit low p27kip1
expression levels. The inactivation of p27kip1 may also occur at
cytoplasmic retention as a consequence of p27kip1 phospho-
rylation by Akt and its binding to 14-3-3 (16). This mechanism
has been associated with a poor patient outcome in breast
cancer (17). Additionally, the PI 3-K/PTEN/Akt pathway
regulates p27kip1 protein stability at a transcriptional level.
Akt is known to down-regulate p27kip1 transcription by the
phosphorylation-dependent inhibition of the Forkhead family
of transcription factors (18). Akt lies downstream of PI 3-K
and EGFR, which act as oncogenes in numerous cancers,
including HNSCC.
In a previous study, carried out in our laboratory, we deter-
mined the expression status of p110α (the catalytic subunit of
PI 3-K), PTEN and pAkt in a series of HNSCC, and we
identified this pathway as one of the most frequently altered
in this type of tumor (19). These circumstances prompted us
to examine the expression levels of p27kip1 and of molecules
that may be important for its regulation in the context of
HNSCC, such as Skp2 and EGFR. Their clinical significance
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and their potential utility as molecular prognostic markers for
the clinical management of HNSCC patients were assessed.
Materials and methods
Patients. Surgical tissue specimens from 45 patients with
HNSCC, who consecutively underwent resection of their
tumors at the Hospital Universitario Central de Asturias
(HUCA) between 2000 and 2003, were prospectively obtained
for our study with institutional review board approval for
guidelines on ethical procedures. Informed consent was
obtained from each patient. No patient had received radio/
chemotherapy prior to intervention or were thought to have
distant metastasis at the time of diagnosis. Surgical samples
were sharply excised, placed in sterile tubes and frozen
immediately in liquid nitrogen. The cases were confirmed to
be neoplastic by the pathologist. Additionally, paraffin-
embedded tissues from 62 patients (including the 45 mentioned
before) were obtained from Servicio de Anatomía Patologica
at the same hospital. Information was obtained from clinical
records.
The characteristics of the patients studied, the clinico-
pathological features of their tumors [TNM staging system of
the International Union Against Cancer (6th edition) (20)] and
median follow-up periods (months) are shown in Table I. Two
patients, who did not smoke or drink alcohol, were excluded
from the analysis, to make the population more uniform. Thus,
the patients in the study were regular tobacco and/or alcohol
consumers. Twenty-eight patients were deceased at the end of
follow-up.
Protein extraction and Western blot analysis. Samples were
processed as previously described (19). Whole protein extracts
(25 μg) from tumor and patient-matched normal epithelia
were electrophoresed and immunoblotted with rabbit anti-
human p27kip polyclonal antibody [Santa Cruz sc-528 (C-19)]
(1:2000). Antirabbit immunoglobulin IgG secondary antibody
was used (1:2000). For the protein load control, anti-ß-actin
mouse monoclonal antibody (Sigma Chemical Co., St. Louis,
MO) was used. Immunoreactive bands were visualized using
the enhanced chemiluminescence Western blot analysis system
(ECL Plus, Amersham Pharmacia Biotech, Arlington Heights,
IL).
Immunohistochemical analysis. Serial formalin-fixed paraffin-
embedded sections (4 μm) were incubated overnight at 54-
56˚C, deparaffinized in xylene and rehydrated through
decreasing graded ethanol solutions. Endogenous peroxidase
activity was suppressed by incubation for 10 min with the
peroxidase block reagent (3% hydrogen peroxide) (Dako).
After antigen retrieval (boiling in 10 mM citrate buffer, pH 6.0
for p27kip, Skp2 or proteinase K treatment, for EGFR), the
sections were processed on a Dako TechMate 500 immuno-
stainer to obtain uniform staining. Non-specific staining was
blocked with ChemMate™ wash buffer 1. Immunostainings
were performed with the following specific primary antibodies:
rabbit polyclonal antibody against human p27kip protein [Santa
Cruz sc-528 (C-19) (1:750 dilution) (4˚C, overnight)], mouse
monoclonal antibody against Skp2 (1G112E9, Zymed
Laboratories Inc.) (1:100), mouse monoclonal antibody against
an epitope on the extracellular domain of human EGFR (kit
EGFR PharmDx™ K 1494, clon 2-18C9) (30 min). The
sections were then incubated with the peroxidase-labelled
polymer conjugated goat anti-rabbit/mouse secondary
antibody for 30 min at room temperature. The stained proteins
were visualized using the DAB solution provided in the kit,
and lightly counterstained with haematoxylin.
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Table I. Characteristics of the patient population and their
tumors (N=62).
–––––––––––––––––––––––––––––––––––––––––––––––––
Feature Frequency (%)
–––––––––––––––––––––––––––––––––––––––––––––––––
Gender
Male 60 (96.77)
Female 2 (3.23)
Anatomic site
Pharynx 40 (64.5)
Larynx 22 (35.5)
pT category
T1 4 (6.45)
T2 13 (20.97)
T3 23 (37.1)
T4 22 (35.48)
pN category
N0 (free margins) 24 (38.71)
N1-3 38 (61.29)
TNM stagea
I 2 (3.23)
II 7 (11.29)
III 11 (17.74)
IV 42 (67.74)
TNM stagea
I-III 20 (32.25)
IV 42 (67.75)
Histopathological grade
Well 26 (41.94)
Moderate 27 (43.55)
Poor 9 (14.51)
Recurrence
No 31 (50)
Yes 31 (50)
Mean age at resection (yrs) 59
Median age at resection (yrs) 61
Median length of follow-up (range)
Total population 33 months (1-78)
Alive at last follow-up 67 months (48-78)
Deceased due to index tumor 18 months (4-60)
Deceased due to other causes 25 months (1-66)
–––––––––––––––––––––––––––––––––––––––––––––––––
aUICC, 6th edition.
–––––––––––––––––––––––––––––––––––––––––––––––––
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To ascertain the specificity of the antibody immuno-
reactivity, negative controls were carried out by exclusion of
the primary antibody. In this case, immunolabelling was
completely abolished. Normal squamous epithelium, colon
carcinoma tissue and infiltrating ductal breast carcinoma were
also included as appropriate positive controls for p27kip, EGFR
and Skp2, respectively.
Each case was scored as a product of two parameters: the
extent of immunostaining (on a 0-100 point scale, after
counting cells in five random fields per sample with the help
of the image tool 3.0 UTHSCSA application) and staining
intensity (on a 1-4 point scale). Values ranged from 0 to 250
for p27kip1, 0 to 249 for Skp2 and 100 to 300 for EGFR.
These continuous variables were categorized as low- and
high-expressing tumors, according to the median values of the
registered scores (30, 37 and 230 for p27kip1, Skp2 and EGFR,
respectively).
Statistical analysis. The clinicopathological features were
dichotomized as follows: pT category, 1-3 vs. 4; pN category,
0 (free lymph nodes) vs. 1-3 (affected lymph nodes) and stage
I-III vs. IV. The molecular data distributed among the different
clinical groups of tumors were tested for significance by
employing the χ2 test, Student's t-test (two-tailed Mann-
Whitney for non-parametrical variables) or ANOVA, where
appropriate. A multivariate analysis (forward Wald method)
was carried out to test the independent significance of
molecular findings or clinicopathological parameters on the
nodal status or local recurrence.
Survival curves were calculated using the Kaplan-Meier
product limit estimate. Succumbing to causes other than the
index tumor or its metastases were not considered treatment
failures, and these patients were censored in any analysis
involving the length of survival. Differences between the
overall survival times were analyzed by the log-rank method.
The multivariate Cox proportional hazard model was used to
examine the relative impact of those variables demonstrated
to be statistically significant in univariate analysis. Statistical
analysis was carried out with the help of the software package
SPSS 12.0 (SPSS, Inc., Chicago, IL). All tests were two-
sided and p<0.05 values were considered to be statistically
significant.
Results
p27kip1 protein expression is frequently reduced in HNSCC.
Western blot analysis of p27kip expression was performed in
45 paired samples of tumor and adjacent normal mucosa. A
reduced p27kip1 expression was detected in 20 tumors (44.4%)
(Fig. 1). This observation was confirmed by immunohisto-
chemical analysis in 47 samples. The p27kip1 expression was
scored as low in 40.43% (19/47) and high in 59.57% (28/47)
(Fig. 2). The p27kip1 distribution in normal epithelium was
detected as a strong positive signal in the most external layers
that progressively diminished towards the actively dividing
basal cells. Regarding p27kip1 subcellular localization, a nuclear
staining pattern was observed in the p27kip1-positive cases,
and additional cytoplasmic p27kip1 was found in 7/38 tumors
that showed any detectable p27kip1 signal. These cases showed
a tendency toward higher p27kip1 levels (considered as a
continuous variable) than those for which only nuclear locali-
zation was observed [U, 63 (p=0.075)].
Immunohistochemical comparison of the p27kip1, Skp2 and
EGFR protein expression in invasive HNSCC and dysplastic
mucosa. In addition to the cytoplasmic retention, Skp2-
dependent ubiquitination/degradation of p27kip1 constitutes
another plausible mechanism to explain the reduced p27kip1
expression observed in our series of HNSCC or molecules
such as EGFR (initiator of PI 3-K/Akt/PTEN pathway) being
able to influence p27kip1 protein levels. Thus, we carried out
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Figure 1. Western blot analysis of the p27kip1 protein expression in HNSCC.
Whole cell lysates containing 25 μg of protein from tumors (T) and patient-
matched normal epithelia (N) were subjected to Western blot analysis. The
indicated proteins (bottom, ß-actin as the loading control) were detected using
specific primary antibodies and were visualized using HRP-conjugated
secondary antibodies as described in Materials and Methods. The case
numbers are shown at the top.
Figure 2. The immunohistochemical detection of p27kip1, Skp2 and EGFR,
showing null/low or high levels of protein expression. While p27kip1 and Skp2
display a nuclear pattern, EGFR expression is detected at the cell membrane;
scale bar, 250 μm.
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an immunohistochemical analysis of Skp2 and EGFR. Tumors
were classified as low or high Skp2-expressing in 23/47
(48.94%) and 24/47 (51.06%) cases, respectively. EGFR
expression was found to be low in 24/47 (51%) and high in
23/47 (49%) of the cases (Fig. 2). To easily visualize and
compare the sites and subcellular distribution, consecutive
sections of a tumoral field were stained with p27kip1, Skp2 and
EGFR as shown in Fig. 3A. Strong EGFR membrane staining
clearly delineates the tumor mass, which is negative in the
infiltrated lymphocytes. This is in marked contrast to p27kip1
immunostaining, which exhibits a nuclear pattern of low/
moderate intensity in tumor cells and a strong positive staining
in the lymphocytes. An inverse cellular distribution of p27kip1
and Skp2 was observed in agreement with the postulated role
of Skp2-mediating p27kip1 degradation. The Skp2 signal
localizes in the nucleus, with a stronger staining intensity at
the invasive edge of the tumor in those cells lacking p27kip1.
We also compared the changes in the expression pattern
of p27kip1, Skp2 and EGFR in the early stages of tumorigenesis.
The consecutive sections of a representative premalignant
dysplastic lesion stained with the same antibodies are shown
in Fig. 3B. It is noteworthy that no Skp2 immunoreactivity
was detected in any dysplastic squamous epithelium, whereas
the staining patterns for the rest of the molecules resembled,
in both level and distribution, those observed in invasive
HNSCC.
Correlations of molecular findings with clinicopathological
features and overall survival outcome. Cross-tabs between
molecular findings and clinicopathological data are shown in
Table II. There was a tendency toward higher EGFR levels in
lymph node-positive cases [3.037 (p=0.081)].
Skp2 expression was higher in those cases with tumor
recurrence [4.821 (p=0.013)]. While 36/40 (90%) pharyngeal
tumors were stage IV, only 6/22 (27.3%) laryngeal tumors
belonged to this group (p=0.000). The tumor site correlated
with the positive lymph nodes: 30/40 (75%) pharyngeal tumors
were lymph node-positive versus 8/22 (36.4%) with laryngeal
localization (p=0.000).
The multivariate analysis (forward Wald method) demon-
strated that only the anatomic site (pharynx vs. larynx) was
associated with an increased risk of developing lymph node
metastasis (0.001), excluding EGFR expression or the histo-
pathological grade. However, none of the following factors:
Skp2 expression, anatomic site, nodal status or tumor stage
(which were statistically related to recurrence in univariate
analysis) established an independent prognostic value for the
incidence of local recurrence in multivariate analysis.
The five-year overall survival rate for the HNSCC cases
with follow-up data was 38% (SE, 0.0952). The relationships
between the protein expression levels of the studied markers
and overall survival rates were examined. The cumulative
survival rate of patients with Skp2 overexpression was
significantly lower than that of the cases with low Skp2
expression [mean, 23 (±5) months vs. 45 (±5) months) [4.85
(0.0276)]]. Fig. 4 shows the Kaplan-Meier survival curves of
the patients grouped by Skp2 immunoreactivity. 
Similarly, patients with tumors arising in the pharynx
presented a reduced cumulative survival rate when compared
with laryngeal tumors [media of 31 (±5) vs. 54 (±5) months,
5.93 (0.0149)]. Other variables with an impact on overall
survival rates were nodal status [5.46 (0.019)], and advanced
tumor stage [7.17 (0.0074)]. These observations reveal that the
tumor population under study is representative, since it follows
the expected behaviour according to the well-established
impact of these clinicopathological features on the overall
survival of HNSCC patients.
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Figure 3. Immunohistochemical comparison of the p27kip1, Skp2 and EGFR
protein expression. (A) Consecutive tissue sections of a representative
invasive HNSCC. p27kip1 and Skp2 displayed an inverse pattern of cell
distribution. A strong nuclear Skp2 signal is observed in cells located at the
invasive edge of the tumor lacking p27kip1-positive staining. The strong
p27kip1 immunoreactivity detected in infiltrated lymphocytes serves as a
positive internal control. EGFR showed a membranous tumor-specific
staining (no signal in lymphocytes). (B) Consecutive tissue sections of a
representative premalignant dysplastic lesion. An absence of Skp2
immunoreactivity was observed in the dysplastic epithelium. p27kip1
exhibited a positive signal in the most differentiated cell layers of the
normal squamous epithelium that diminished toward the dysplastic areas,
where EGFR immunoreactivity is higher (x45 magnification).
Figure 4. Kaplan-Meier disease-free survival curves of the patients with a
low or high Skp2 immunoreactivity; p=0.0324, log-rank method.
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A multivariate model using Cox regression analysis
(forward stepwise method) was used to evaluate the statistical
strength of independent associations between covariates and
survival. The only parameter with independent prognostic
value was Skp2 expression of the primary tumor (p=0.048;
95% CI, 1.011-6.911) when it was tested along with the
variables of anatomic site (p=0.139), nodal status (p=0.155)
and tumor stage (p=0.207).
Discussion
The abundance of p27kip1 is controlled in a cell-type and signal-
specific manner by the integration of mitogenic and antimito-
genic signaling pathways that affect its translation, stability
and localization. The inactivation of p27kip1 can be achieved by
a number of different oncogenic stimuli, including the loss of
PTEN, up-regulation of EGFR, Skp2 or Akt activity. The
fact that most of the control of p27kip1 abundance is post-
transcriptional suggests that a proteomic survey would be an
adequate approach to study p27kip1 expression and its potential
prognostic value (21). To accomplish this, we performed a
p27kip1 protein analysis using immunohistochemistry and
Western blot analysis. The two techniques revealed a similar
proportion of tumors with reduced p27kip1 levels (40.43 and
44.4%, respectively).
In breast cancer, where reduced p27kip1 levels constitute an
independent poor prognostic indicator (4), it has been suggested
that its accelerated proteolysis reflects an increased PI 3-K
activity (16). We did not find any association between the
p27kip1 down-regulation and alterations of the PI 3-K/Akt
pathway [detected in a previous study as pAkt, or p110α
accumulation or PTEN down-regulation (19)], a similar result
to that reported in thyroid cancer (22). Additionally, this is
the first report showing p27kip1 cytoplasmic retention in
HNSCC (7/38 cases). Although it has been described that the
cytoplasmic localization of p27kip1 predicts a poor prognosis
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Table II. Correlations of EGFR, p27kip1 and Skp2 expression (IHC analysis) with clinicopathological findings.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
EGFR p27kip1 Skp2
–––––––––––––––––––––– –––––––––––––––––––––––– –––––––––––––––––––––––
Low High Low High Low High
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Anatomic site
Pharynx 17 15 13 19 15 17
Larynx 7 8 6 9 8 7
p 0.680 0.968 0.680
pT category
T1 1 1 0 2 1 1
T2 5 5 4 6 7 3
T3 8 9 8 9 7 10
T4 10 8 7 11 8 10
p 0.967 0.640 0.507
pN category
N0 11 5 6 10 9 7
N1-3 13 18 13 18 14 17
p 0.081 0.769 0.471
Histopathological grade
Well 8 11 6 13 7 12
Moderate 12 9 8 13 11 10
Poor 4 3 5 2 5 2
p 0.599 0.177 0.269
TNM stage
I-III 7 6 7 6 8 5
IV 17 17 12 22 15 19
p 0.813 0.246 0.285
Recurrence
No 12 10 8 14 15 7
Yes 12 13 11 14 8 17
p 0.654 0.590 0.013
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
p, χ2 test.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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in late-stage ovarian carcinoma (23), we did not observe any
impact on prognosis in our HNSCC series. Moreover, no
relationship was established between p27kip1 mislocalization
and alterations of the PI 3-K/Akt pathway. This result is in
agreement with other reports in glioblastoma cells showing
that p27kip1 cytoplasmic localization does not change in
response to PI 3-K activity (24).
A high Skp2 expression was observed in 51.06% of the
cases and an inverse expression pattern to p27kip1 immuno-
staining was observed in certain tumor areas (Fig. 3A). No
correlation was found between Skp2 expression and any PI
3-K/Akt alteration. Significantly, Skp2 immunoreactivity
was not detected in premalignant lesions that are often found
in the vicinity of tumor tissues (Fig. 3B). This suggests that
Skp2 overexpression accompanies tumorigenesis. Moreover,
Skp2 is associated with tumor recurrence (p=0.013) and with a
shorter cumulative survival rate (p=0.032). Notably, Skp2 was
the only independent prognostic factor on a multivariate Cox
model basis (p=0.048). These results are in agreement with
those obtained by Kudo et al (25), suggesting that Spk2 is a
novel marker of poor prognosis in HNSCC management.
EGFR is the target of antitumoral drugs, such as erlotinib.
Its therapeutic activity results from EGFR inhibition followed
by p27kip1 up-regulation, as has recently been demonstrated in
NSCLC cell lines (26). In HNSCC, a high expression of EGFR
has been described, although its association with disease
outcome remains controversial (27,28). In our HNSCC series
we detected high EGFR immunostaining in 49% of the cases.
EGFR immunostaining tended to be more frequent in lymph
node-positive cases (p=0.081). It has been reported that EGFR
inhibition blocks the proliferation and survival of cancer cells
and this is associated with an increased p27kip1 expression,
suggesting a mechanistic connection between these two
events (29). In agreement with this idea, Fig. 3A shows an
inverse pattern of EGFR and p27kip1 staining, along with a
partially coincidental pattern of the Skp2 protein.
As expected, tumors arising at the pharynx presented
lymph node involvement (p=0.000), a more advanced global
disease stage and a poorer prognosis (p=0.000) more frequently
than laryngeal tumors. Taken together, these data indicate
that the tumor population under study is representative and
shows the expected behavior.
This report points to a Skp2 protein level immunohisto-
chemical evaluation as a potential marker of poor prognosis for
head and neck squamous cell carcinoma. Further studies
validating these results on an independent HNSCC population
are warranted.
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